Abstract

Purpose: To establish whether Curaderm, a topical pharmacotherapy for skin cancer, irritates or sensitizes normal skin. Methods: The dermal irritation and skin sensitization toxicity of Curaderm were investigated in rabbits and guinea pigs in compliance with the Organization for Economic Cooperation and Development guideline. To assess dermal irritation, rabbits were dermally exposed to Curaderm for varying periods of time. To assess hypersensitivity, the guinea-pig maximisation test was applied. Results: Curaderm was only negligibly irritating using the criteria of erythema and oedema. Curaderm did not produce any sensitization toxicity of the skin. Conclusion: These studies confirm the non-toxic observations on normal skin experienced in the clinical setting when treating skin cancer and reinforce the specificity of Curaderm towards cancer cells.

Highlights

  • IntroductionBEC, the initials of the inventor of this technology, is composed mainly of solamargine and solasonine [1]

  • In 1987, it was reported that plant-derived glycoalkaloids—BEC [1] induced anticancer effects in cell culture [2] [3] [4], animals [5], and humans [6] [7].BEC, the initials of the inventor of this technology, is composed mainly of solamargine and solasonine [1]

  • Curaderm did not produce any sensitization toxicity of the skin. These studies confirm the non-toxic observations on normal skin experienced in the clinical setting when treating skin cancer and reinforce the specificity of Curaderm towards cancer cells

Read more

Summary

Introduction

BEC, the initials of the inventor of this technology, is composed mainly of solamargine and solasonine [1]. The anticancer effect of solamargine is 9 times more potent than solasonine [8]. A plethora of further investigations has taken place resulting in the placement of BEC as a very promising antineoplastic agent with vast potential to serve as a targeted anticancer agent [9]-[23]. Toxicity studies of BEC have been well documented [8]

Methods
Results
Discussion
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call